Fungus Therapeutics develops antibody-based drugs to treat drug-resistant fungal infections. Their focus on fungal cell wall biosynthesis and antibody engineering aims to provide effective treatments for patients with limited options.
Funding
$12.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug-resistant fungal infections pose a significant threat, particularly for immunocompromised individuals, as existing antifungal therapies become less effective. The limited availability of novel antifungal agents exacerbates the challenge of treating these infections, leading to increased morbidity and mortality.
Solution
Fungus Therapeutics is developing a pipeline of antibody-based therapeutics designed to combat drug-resistant fungal infections. Their approach focuses on targeting essential fungal cell wall biosynthesis pathways with engineered antibodies, aiming to disrupt fungal growth and enhance immune-mediated clearance. By leveraging antibody engineering, Fungus Therapeutics seeks to create highly specific and potent antifungal agents that can overcome existing resistance mechanisms and provide effective treatment options for patients with limited alternatives.
Target Audience
The primary target audience includes immunocompromised patients, individuals with drug-resistant fungal infections, and healthcare providers seeking novel antifungal therapies.
Features
- Antibody-based therapeutics targeting fungal cell wall biosynthesis
- Engineered antibodies designed for high specificity and potency against fungal pathogens
- Focus on drug-resistant fungal infections
- Aims to disrupt fungal growth and enhance immune-mediated clearance